Latest Past Events

ICER Virtual Public Meeting

ICER plans to assess the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol®, Esperion Therapeutics), and bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) for the treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD. Inclisiran is currently undergoing FDA review, with an anticipated decision expected at the end of this year. Bempedoic acid received FDA approval in February 2020. Interventions of interest: … Read More